234 related articles for article (PubMed ID: 26316712)
1. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Chen J; Lu Y; Zheng Y
Drug Des Devel Ther; 2015; 9():4751-60. PubMed ID: 26316712
[TBL] [Abstract][Full Text] [Related]
2. Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.
Peng L; Qin BD; Xu S; Xia Y; Yang JS; Xiao K; Stebbing J
Oncol Res Treat; 2022; 45(5):281-290. PubMed ID: 35114663
[TBL] [Abstract][Full Text] [Related]
3. Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Cao C; Wang J; Bunjhoo H; Xu Y; Fang H
Acta Oncol; 2012 Feb; 51(2):151-6. PubMed ID: 22085338
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
7. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis.
Qu CY; Zheng Y; Zhou M; Zhang Y; Shen F; Cao J; Xu LM
World J Gastroenterol; 2015 Apr; 21(16):5072-80. PubMed ID: 25945023
[TBL] [Abstract][Full Text] [Related]
8. [Bevacizumab and arterial hypertension or proteinuria: management].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S; Sher A; Chu D; Wu S
Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
[TBL] [Abstract][Full Text] [Related]
10. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
12. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Wang S; Yang Z; Wang Z
Oncotarget; 2015 Jul; 6(20):18206-23. PubMed ID: 26156021
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.
Zhang H; Huang Z; Zou X; Liu T
Oncotarget; 2016 Dec; 7(50):82473-82481. PubMed ID: 27756883
[TBL] [Abstract][Full Text] [Related]
14. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.
Carroll NM; Delate T; Menter A; Hornbrook MC; Kushi L; Aiello Bowles EJ; Loggers ET; Ritzwoller DP
J Oncol Pract; 2015 Sep; 11(5):356-62. PubMed ID: 26060223
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis.
Wang ZP; Zhang HF; Zhang F; Hu BL; Wei HT; Guo YY
Eur J Clin Pharmacol; 2015 May; 71(5):517-24. PubMed ID: 25845654
[TBL] [Abstract][Full Text] [Related]
16. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
Muto S; Takagi H; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Anticancer Res; 2017 Jun; 37(6):3169-3174. PubMed ID: 28551660
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma.
Li LJ; Chen DF; Wu GF; Guan WJ; Zhu Z; Liu YQ; Gao GY; Qin YY; Zhong NS
J Thorac Dis; 2018 Aug; 10(8):5010-5022. PubMed ID: 30233875
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
20. Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data.
Liu M; Zheng Y; Chen Z; Qiu Y; Pan Z; Cai Z; Shi Y; Cheng J; Yao W
Tumour Biol; 2017 Jul; 39(7):1010428317714897. PubMed ID: 28714372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
